Articles tagged with Ovarian Cancer
A recent study found that only 8% of disabled or older women who qualified for Medicare received BRCA1 and BRCA2 testing between 2000 and 2014. Women with these mutations are at higher risk for developing second breast cancer and ovarian cancer, making timely testing crucial for informed decision-making.
Researchers found that normal fallopian tubes can contain pre-cancerous cells that escape and later progress to cancer in the pelvic or abdominal cavity. This 'precursor escape' concept may help explain why some women present with advanced ovarian cancer beyond the fallopian tubes.
Researchers at Johns Hopkins and Insilico Medicine discovered novel epigenetically silenced genes in ovarian cancer, including methylation of the GULP1 gene. GULP1 expression is associated with late-stage disease and poor overall survival, suggesting its potential as a biomarker.
Researchers have discovered that women with low-grade serous ovarian cancer and a BRAF gene mutation experience excellent responses to BRAF inhibitor treatments. This finding is encouraging for patients who may not respond to conventional chemotherapy.
Researchers at Rockefeller University have discovered the molecular means by which some cancers caused by BRCA1 mutations evade treatment by PARP inhibitors. The study challenges previous assumptions about the mechanics of these drugs and provides a foundation for advancements in PARP inhibitor therapy.
A large population study from Denmark found no causal association between assisted reproduction treatment and increased risk of ovarian cancer. Female infertility, rather than ovarian stimulation, was associated with an increased risk of ovarian cancer.
Researchers at Mayo Clinic have discovered how the DNA repair protein 53BP1 relocates to chromosomes to fix damage, using RNA molecules as an off/on switch. This finding could lead to new therapies for ovarian cancer by targeting a specific protein called TIRR.
A study of 99,654 individuals found that lifetime light alcohol drinkers had the lowest combined risk of mortality or developing cancer. The risk increased linearly with lifetime alcohol consumption, with heavy and very heavy drinkers facing significantly higher risks.
Researchers found a link between calcitriol and reduced ovarian cancer progression by blocking smad signaling in tumor cells and supportive fibroblasts. The study opens a new potential avenue for treating ovarian cancer, with calcitriol already FDA-approved for other uses.
The American Cancer Society report highlights a decline in ovarian cancer incidence and mortality rates in the US, with significant reductions seen among white populations. The strongest risk factor for ovarian cancer is a family history of breast or ovarian cancer, with BRCA1 and BRCA2 mutations accounting for nearly 40% of cases.
A population-based registry study confirms that secondary surgery can delay recurrence by two years and improve median overall survival by at least six years. The treatment model is centralized in Norway, which led to the favorable results, and may be adopted by other countries.
A cancer patient with advanced ovarian cancer responded well to treatment with hydroxychloroquine and quinacrine, initially prescribed for an autoimmune disease. The case report suggests that repurposing antimalarial drugs may improve cancer outcomes.
A phase II clinical trial suggests patients with aggressive pancreatic cancer who harbor BRCA mutations may benefit from rucaparib, a PARP inhibitor approved for ovarian cancer. The study found 32% of patients experienced a clinical benefit, including four patients with responses and two with stable disease.
Researchers have identified a key protein, MIP-1β, that enables ovarian cancer cells to spread through the peritoneal cavity by making mesothelial cells sticky. This discovery could lead to new therapies targeting this protein and its related adhesion protein P-selectin.
The study shows that ST1-ADC selectively inhibits tumor cell proliferation and induces tumor cell death in both in vitro and in vivo ovarian cancer models. The data provide promising results for the development of new therapeutic options to treat ovarian cancer.
PARP-1 levels are linked to targeted therapy resistance in ovarian cancer. Researchers have developed a method to image and measure PARP-1 using PET scans, which may predict efficacy and resistance to PARP inhibitors.
Researchers found that hemp extract slowed cell migration and reduced inflammation in ovarian cancer cells, suggesting a possible biological mechanism behind its anti-cancer effects. The study's results are comparable to or even better than current ovarian cancer drug Cisplatin, with potential for fewer side effects.
Researchers found tumors with PTEN loss are less likely to generate an immune response, suggesting PTEN levels can predict treatment outcome. The study's findings may improve personalized medicine for BRCA-deficient ovarian cancer patients.
The Rivkin Center awarded $1.185 million to ovarian cancer researchers worldwide, focusing on prevention and early detection, DNA repair, and novel therapies. This funding aims to improve early detection and discover new treatments for the deadly gynecological cancer.
Researchers developed a novel personalized vaccine made from tumor tissue and immune cells, inducing potent immune responses in patients with recurrent ovarian cancer. The vaccine showed promise in extending overall survival and improving progression-free survival.
Ludwig scientists present new data on cancers including colorectal, brain, breast, and ovarian cancer, as well as innovative clinical trials and novel approaches to cancer immunotherapy. The research focuses on mobilizing immunity against ovarian cancer and personalizing cancer treatment strategies.
A new personalized vaccine has shown promise in boosting immune responses and increasing survival rates in patients with advanced ovarian cancer. The vaccine combines different immunotherapies to better tackle the disease, which is often diagnosed at later stages and lacks curative treatment options.
The Translational Genomics Research Institute (TGen) will receive $450,000 to fund a clinical trial for a newly developed ovarian cancer drug treatment, thanks to Colleen's Dream Foundation. The foundation has funded TGen in the past and has awarded over $1.2 million in grants to 27 institutions.
Researchers at Baylor College of Medicine have identified a key regulator of a cellular pathway that selectively targets mutant p53-R175H proteins, which promote ovarian cancer growth. The study suggests designing drugs directed at this regulator might lead to better ways to control cancer growth.
Researchers at The Wistar Institute have found that HDAC inhibitors can suppress proliferation and induce programmed cell death in ovarian cancer cells with ARID1A gene mutations. This new treatment approach has therapeutic potential, slowing tumor growth and improving survival rates in mouse models.
Researchers developed a new screening test for endometrial and ovarian cancers using cervical fluid samples from routine Pap tests. The test, called PapSEEK, detected cancer cells in 81% of endometrial and 33% of ovarian cancers, with improved sensitivity when using different sampling methods.
A new study from Virginia Tech found that fluid shear stress causes cancerous cells to become more aggressive and benign cells to exhibit traits of cancer. This discovery could lead to the development of a predictor for ovarian cancer, enabling earlier diagnosis and potentially saving thousands of lives.
A TGen-led study found that ponatinib significantly delays tumor growth and reduces tumor volume in SCCOHT, suggesting it should be tested for use in clinical trials. The rare form of ovarian cancer has a dismal two-year survival rate of less than 35 percent and affects young women and girls.
A new mutation on the X-chromosome has been identified as a potential contributor to earlier onset ovarian cancer in women. The study also found an association between this mutation and higher rates of prostate cancer in fathers and sons.
The US Preventive Services Task Force recommends against screening for ovarian cancer in women without symptoms and at low risk. The task force found that the harms of screening, including unnecessary surgery, outweigh its benefits.
A study found that screening the general population for cancer genes is cost-effective, preventing more breast and ovarian cancers. This approach could lead to thousands fewer cases of these cancers, particularly among women over 30.
Researchers found that population testing for multiple cancer genes is the most cost-effective strategy, preventing many more ovarian and breast cancers than current screening methods. This approach could save thousands of lives by reducing risk factors through enhanced screening, medical prevention, or risk-reducing surgery.
Researchers found that normal tissue BRCA1 methylation is associated with an increased risk of high-grade ovarian cancer, which may occur as a prenatal event. The study analyzed white blood cells from patients and healthy controls and discovered that elevated BRCA1 methylation was confined to those diagnosed with high-grade serous tumors.
A prospective cohort study found that young women diagnosed with breast cancer who carry a BRCA mutation have the same chances of survival as women without the mutation. After treatment, women with early breast cancer and BRCA mutations do not have a significant difference in overall survival compared to those without the mutation.
Researchers have discovered a key cellular receptor involved in ovarian cancer metastasis, CXCR4, which can be targeted with inhibitors to reduce tumor cell dissemination. High expression of CXCR4 is associated with aggressive variants of the disease.
Researchers found a novel combination of PARP and BET inhibitors to be effective in treating ovarian cancers without BRCA1 and BRCA2 gene mutations. The combination resulted in enhanced sensitivity of cells to cell death, offering potential applications in broadening treatment options for various malignancies.
A new treatment approach for ovarian cancer has shown promising results in a mouse model. Combining drugs that reactivate dormant genes with those that activate the immune system led to greater tumor reduction and longer survival rates compared to single-drug treatments.
Large racial disparities were found in the survival of patients with ovarian, colon, and breast cancers in the United States. Black women had consistently worse survival compared to white women, despite similar stage distributions. The five-year net survival for black women was lower than for white women in all three types of cancer.
Researchers identified several lncRNAs linked to ovarian cancer, including DNM30S, which correlates with worse survival rates. Targeting these lncRNAs may represent a viable treatment strategy for ovarian cancer.
A study in Malaysia assesses the effectiveness of mainstreaming genetic counselling for ovarian cancer patients. Preliminary results show that most patients are satisfied with their experience, regardless of whether they receive counselling by a trained clinician or a genetic counsellor.
A computer program called DrugPredict has been developed to repurpose FDA-approved drugs for new indications, including the potential treatment of epithelial ovarian cancer. The researchers found that common pain medications like aspirin can kill ovarian cancer cells, and NSAIDs may also have applications in this area.
Researchers have developed a method to grow hundreds of lab-grown cancer spheroids from just a few tumor cells derived from a patient. These 3-D cultured cells can accurately mirror the response of natural cells implanted in mice, making them a potential tool for testing individualized treatments.
A recent study found that dietary isoflavone intake was associated with an elevated risk of advanced prostate cancer, but not non-advanced cases. Isoflavones are a type of phytoestrogen found in soybeans and other plants.
Zepsyre, a marine-derived anticancer drug, will be commercialized in South Korea under the deal. PharmaMar retains exclusive production rights and will sell to Boryung Pharm for commercial use.
A new blood test has been developed to detect ovarian cancer with high accuracy, using microRNA profiling to distinguish between cancerous and benign tumors. The test shows promise in accurately predicting ovarian cancer, even when other methods fail.
Researchers discovered that tumor cells in the fallopian tubes of women at high-risk for ovarian cancer can be detected years before they develop into the disease, providing a potential window of time for early detection and intervention. The study identified TP53 gene mutations as an early indicator of ovarian cancer development.
A study of nine women suggests that ovarian tumors may originate in the fallopian tubes, providing insights into cancer origin and potential prevention strategies. The researchers found identical genetic errors in chromosome 17 and BRCA genes in all patients, supporting the fallopian tube theory.
A study analyzing BRCA testing trends from 2003 to 2014 found a significant spike in testing following the publication of Angelina Jolie's op-ed on gene testing. The test increased 80-fold, with rural areas showing higher follow-up surgical procedure rates compared to urban areas.
A new study suggests that many pelvic tumors in women may have a common origin in the fallopian tubes, which could lead to new strategies for preventing and early detecting ovarian cancer. The research found that ovarian cancer cells share genetic similarities with cells covering the tips of fallopian tubes.
A recent study led by Mayo Clinic researchers found that tumor-infiltrating lymphocytes present in high-grade ovarian cancer tumors can predict patient survival. The study analyzed over 5,500 patients from nine countries and discovered that higher levels of these immune cells were associated with better outcomes.
Yale researchers have identified the molecular mechanism driving BRCA1 gene mutations' association with breast cancer, offering hope for personalized treatment plans and increased cancer detection accuracy.
A nanotechnology-enhanced biochip developed by NJIT engineer Eon Soo Lee can detect deadly diseases such as ovarian cancer and pneumonia early in their progression. The device, which analyzes a tiny amount of blood within two minutes, has the potential to improve treatment outcomes significantly.
Researchers at Notre Dame's Harper Cancer Research Institute have made a breakthrough in understanding how ovarian cancer cells spread throughout the body. They found that a specific membrane proteinase called MT1-MMP plays a crucial role in regulating the transition of cancer cells from floating to sticking phases.
A study published at ESMO 2017 Congress found that abdominal fat distribution is a significant predictor of cancer diagnosis in postmenopausal women. The study, which included 5,855 women, showed that the ratio of abdominal to peripheral fat was an independent risk factor for certain cancers.
The ARIEL3 trial shows rucaparib maintenance therapy significantly improves progression-free survival in patients with high-grade ovarian cancer and BRCA mutations. The medication also benefits patients with homologous recombination deficient tumors, increasing overall response rates.
The ICON8 trial confirms standard dosing of paclitaxel is safe and effective for European patients with ovarian cancer. The study found no benefit to dose-dense regimens in terms of progression-free survival, but noted a slight increase in grade 3-4 toxicity.
Despite high-risk genetic mutations detectable through simple blood or saliva tests, only 15% of affected women in US have taken recommended genetic test. A new study from UCLA Fielding School of Public Health highlights a significant unmet need for genetic testing across the country.
Researchers at The Wistar Institute have discovered a potential new therapeutic strategy for ovarian clear cell carcinoma, a difficult-to-treat form of ovarian cancer. By targeting the activity of histone deacetylase 6, a protein that suppresses tumor suppressive functions, they were able to increase apoptosis in tumor cells and reduce...
A new study offers a decision-analytic model to help women with BRCA mutations determine the optimal age for preventive surgeries that can significantly reduce lifetime breast and ovarian cancer risk. The model recommends specific ages for bilateral mastectomy (BM) and salpingo-oophorectomy (BSO) procedures.
Researchers from UT Health San Antonio found that BRCA1 mutation carriers experience higher gene expression-related stress in luminal epithelial cells, which are more prone to breast tumors. This stress is also associated with estrogen-responsive genes in the breasts and ovaries, a key site for cancer predisposition.